Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific PROMUS and TAXUS Express stents ‘perform well’

Boston Scientific PROMUS and TAXUS Express stents ‘perform well’

24th September 2009

Boston Scientific has welcomed the news that its PROMUS and TAXUS Express stents were found to have performed well in a clinical study.

The results of the trial – which involved 3,690 patients and was the largest diabetic subset ever studied in a drug-eluting stent study – showed that the products support the benefits of paclitaxel-eluting stents in diabetic patients.

Donald Baim, managing director and chief medical and scientific officer at Boston Scientific, said: “The strong outcomes among diabetic patients treated with TAXUS Express were impressive, particularly the rates of target lesion failure at one year, which were equivalent for PROMUS and TAXUS Express.”

This news comes after another Boston Scientific product trial showed that cardiac resynchronisation therapy has a positive effect on those suffering from heart failure.

Using the firm’s cardiac resynchronisation therapy defibrillators on patients suffering from the condition brought about a 34 per cent relative fall in the risk of mortality, it was discovered.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.